Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients

Table 1 Basic demographic data and underlying liver status in both groups

	Group I	Group II	P value
	HCC with previous DAAs (n = 151)	HCC without previous DAAS (n = 346)
Age (mean ± SD)	60.17 ± 7.75	59.84 ± 9.12	0.70
Gender			0.33
Female	36 (23.8)	97 (28.0)
Male	115 (76.2)	249 (72.0)
Residence			0.28
Rural	131 (86.8)	287 (82.9)
Urban	20 (13.2)	59 (17.1)
BCLC			< 0.001a
0	5 (3.3)	15 (4.3)
A	47 (31.1)	134 (38.7)
B	17 (11.3)	68 (19.7)
C	49 (32.5)	50 (14.5)
D	33 (21.9)	79 (22.8)
MELD (mean ± SD)	14.35 ± 5.041	36.10 ± 30.22	< 0.001a
CTP score			0.04
A	50 (33.1)	88 (25.4)
B	65(43.0)	138 (39.9)
C	36 (23.8)	120 (34.7)
FIB4			< 0.001c
mean ± SD	3.25 ± 9.87	7.11 ± 7.68
Median	0.023	4.49
IQR	4.51	6.2
HCC detection time after stop of DAAS	Range: 1-72 moMedian: 8 mo	-	-

^aP < 0.05.

^cP < 0.001.

HCC: Hepatocellular carcinoma; MELD: Model for end stage liver disease; CTP: Child Turcotte-pough; BCLC: Barcelona cancer liver clinic.

Table 2 Clinical presentation in both groups

	Group I	Group II	P value
	HCC with previous DAAs (n = 151)	HCC without previous DAAS (n = 346)
Hypertension	56 (37.1)	135 (39.0)	0.68
DM	56 (37.1)	113 (32.7)	0.33
Smoking	73 (48.3)	121 (35.0)	0.005a
Surgical operations	32 (21.2)	101 (29.2)	0.06
Blood transfusion	23 (15.2)	87 (25.1)	0.01a
Jaundice	60 (39.7)	154 (44.5)	0.32
Ascites	90 (59.6)	197 (56.9)	0.58
LL edema	48 (31.8)	143 (41.3)	0.07
Hepatic encephalopathy	14 (9.3)	61 (17.6)	0.01a

^aP < 0.05.

HCC: Hepatocellular carcinoma; DM: Diabetes mellitus; LL: Lower limb.

Table 3 Comparison of laboratory data in both groups

	Group I	Group II	P value
	HCC with previous DAAs (n = 151)	HCC without previous DAAS (n = 346)
HB (mean ± SD)	10.41 ± 1.88	10.78 ± 1.99	0.02a
TLC (mean ± SD)	6.55 ± 6.20	7.74 ± 8.60	0.004b
PLATELETS (mean ± SD)	147.28 ± 79.76	135.95 ± 61.17	0.22
TBIL (median)	3.07	2.5	0.93
DBIL (median)	0.7	0.9	0.84
ALB (mean ± SD)	3.32 ± 1.47	2.98 ± 0.85	0.004b
INR	1.31 ± 0.35	1.44 ± 0.47	0.4
ALT (median)	77	54	0.001c
AST (median)	76	70	0.62
CREAT (mean ± SD)	1.21 ± 0.45	1.43 ± 3.67	0.15
UREA (mean ± SD)	40.81 ± 16.01	54.93 ± 46.17	0.04a
AFP (median)	184.0	60.0	< 0.001c

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

HCC: Hepatocellular carcinoma; CBC: Complete blood picture; TLC: Total leucocytic count; TBIL: Total bilirubin; DBIL: Direct bilirubin; ALB: Albumin, ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alfa feto protein.

Table 4 Radiological characters of hepatocellular carcinoma in both groups

	Group I	Group II	P valuec
	HCC with previous DAAs (n = 151)	HCC without previous DAAS (n = 346)
Number			< 0.001
Single	71 (47.0)	259 (74.9)
Multiple	80 (53.0)	87 (25.1)
Size			< 0.001
Less than 2 cm	1 (0.7)	54 (15.6)
2.5 cm	91(60.3)	177 (51.2)
Greater than 5 cm	59 (39.1)	115 (33.2)
Site			0.001
Bilobar	21 (13.9)	29 (8.4)
Lt lobe	24 (15.9)	23 (6.6)
RT lobe	106 (70.2)	294 (84.9)
PVT	68 (45.0)	75 (21.7)	< 0.001
Splenomegaly			< 0.001
Average	38 (25.2)	98 (28.3)
Mild	113 (74.8)	214 (61.8)
Moderate	0 (0.0)	34 (9.8)

^cP < 0.001.

HCC: Hepatocellular carcinoma; DAAs: Directly acting antiviral agents; PVT: Portal vein thrombosis.